Understanding the impact of disease control: TB epidemiology and the GFATM.

Slides:



Advertisements
Similar presentations
WHO Regional Office for Europe Vaccine preventable diseases and Immunization programme Diphtheria Incidence in the WHO European Region 1990 Source; WHO/UNICEF.
Advertisements

End TB strategy target setting
Monitoring progress towards the coverage and disease incidence targets GLOBAL MEASLES AND RUBELLA MANAGEMENT MEETING March 2011 Geneva, Switzerland.
Multi-drug Resistant Tuberculosis Hail M. Al-Abdely Consultant, Infectious Diseases, KFSH&RC.
Modelling changes in HIV prevalence among women attending antenatal clinics in Uganda Brian Williams.
Vaccine in National Immunization Programme Update March 2015.
World Health Organization
TITLE from VIEW and SLIDE MASTER | August 7, |1 | Countries with Hib vaccine in the national immunization programme; and planned introductions *
WHO Regional Office for Europe Vaccine preventable diseases and Immunization programme Measles containing vaccine (MCV1) coverage in the WHO European Region.
The Global Plan to Stop TB, (1)
1 Global and Regional Tuberculosis (TB) update ACSM workshop, Amman, Jordan April 13-17, 2008 Dr. Sevil Huseynova.
World Health Organization
What can modelling tell us about HIV and TB that we don’t already know?
XDR-TB Extensively Drug-Resistant Tuberculosis What, Where, How and Action Steps…
Highlights of New WPV Cases 34 new cases in 5 countries 14 cases (14 W3) but no new district in India Most recent date of onset 03 Oct 1 case (W1) but.
DOTS Expansion: Monitoring Drugs Leopold Blanc TBS, Stop TB WHO, Communicable Diseases.
Evidence and Information for Policy Christopher J.L. Murray Executive Director Evidence and Information for Policy World Health Organization National Capacity.
World Health Assembly 63 Geneva, Suisse May 2010 WORLD HEALTH EDITORS NETWORK Tracking Global Health News: building health literacy Multi-Drug Resistant.
Global Programme on Evidence for Health Policy Presentation by the Epidemiology and Burden of Disease Team of the World Health Organization at the United.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
Strategic Information and the Control of Tuberculosis Brian Williams and Chris Dye TB programme, Monitoring and Evaluation, WHO.
Moving ahead with the Stop TB Strategy: where are we today? Dr Mario Raviglione Director, WHO Stop TB Department Joint Meeting of Core Teams and High Burden.
WHO and International Panel International Collaborative Effort on Injury Statistics Hyatt Regency, Washington September 7-8, 2006.
Current Health Concerns: Tuberculosis Saharwash Jamali Hamna Jaffar.
Dr Ral Antic Chair Scientific Committee IUATLD-APR Australia Pre-Conference Workshop 1 National TB Control Program Summary & Remarks.
Measles Mortality Reduction: the risk of resurgence Global Immunization Meeting Geneva, Switzerland 1-3 February 2010 Balcha Masresha, WHO/AFRO.
Global Programme on Evidence for Health Policy The use of GIS in the Global Programme on Evidence for Health Policy (GPE) Meeting on Cartography and Geographic.
Vaccine in National Immunization Programme Update April 2016.
Christian Gunneberg, Medical Officer WHO, Geneva STB Department
SAGE 2010 Sampling Distribution
Palliative Care and M/XDR-TB Global burden of M/XDR-TB
financial requirements
Measles disease An acute viral infection spread via respiratory secretions or aerosols Classic manifestations: Maculopapular rash Fever +cough + coryza/conjuctivities.
reporting rate of discarded cases* per 100'000 population**
Nazir Ismail CTB/NICD & WHO-SRL & UP
Ageing Matters Somnath Chatterji Information, Evidence and Research
اپيدميولوژي و كنترل سِل
PROGRESS IN GLOBAL TB CONTROL
SAGE 2009 Sampling Distribution
Countries Having Introduced Hib Vaccine
Countries Having Introduced Hib Vaccine and Infant Hib Coverage, 2010
Sampling Distribution
Non-polio AFP Rate July 2014 – June 2015 July 2015 – June 2016
(70 countries or 36%) (23 countries or 12%)
Countries with Genotype data available
Countries Using Hib Vaccine in National Immunization Schedule in 2010 and Countries Approved for GAVI Support for Use from 2011 Onwards Yes (166 countries.
World Health Organization
World Health Organization
Onset of most recent WPV1 Case Number of WPV infected districts
Countries having introduced HepB vaccine
Four indirect measures of TB incidence
Direct estimates of the burden of disease EURO Workshop November 2003
Kevin M De Cock MD CDC Kenya Nairobi, September 21, 2003
Review of Wednesday 5th May
TB in South Africa.
Mapping Levels of Palliative Care Development: A Global Update
Countries Using Mening Vaccine in National Immunization Schedule 2011
What is “burden”? DALY = YLL (death) + YLD (disability)
Surveys of TB infection and disease
- Use same categories as for bar chart below Introduced Without GAVI
Onset of most recent case Number of infected districts
Four indirect measures of TB incidence
PROGRESS IN GLOBAL TB CONTROL
Managing TB in the era of HIV
THE GLOBAL EPIDEMIOLOGY OF TUBERCULOSIS WORLD HEALTH ORGANIZATION
Meningitis/Encephalitis Surveillance Countries reporting to WHO Network or with Other (non-WHO Network) Surveillance Activities WHO Network (46 member.
Four indirect measures of TB incidence
2,100 4,200 1,050 Kilometers < 90% (75 countries or 39%)
World Health Organization
World Health Organization
Presentation transcript:

Understanding the impact of disease control: TB epidemiology and the GFATM

Questions Routine OR SurveysResearch Size of NotificationsPrivate sect.PrevalenceActive CF the Cure rateVital Reg.Incidence problemDeaths Global Report S. AfricaReview S. Korea Direction NotificationsSent. sitesPrevalenceModelling of changeTr. outcomesIncidence MoroccoChennai S. KoreaWorld Reasons HIV; MDR;Risk factorsHIVDuration dis. for changeDiagnosticsSocial issuesMDR AccessPPM NairobiIndia S. Africa S. Africa Impact ofNotificationsDiagnosisPrevalenceDOTS Control Cure rateDrug supplyIncidenceIPT DeathsQual. control PeruCzech.IndiaCzech.

Size/Routine Highest TB rates per capita are in Africa 25 to to to 299 < to or more No Estimate per population The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. © WHO 2002

Size/OR Table 1. Estimating case detection rates from vital registration data. Red: Statistics South Africa. Blue: TB programme. Errors are fractional errors. 2001Error (%) TB deaths (k) All deaths (k)451.9 Unknown causes (k)56.2 Deaths due to HIV9.220 Completeness of reporting (%)90.05 Proportion of HIV deaths due to TB TB deaths (k)66.1 Proportion of cases HIV positive (%) CFR negative (%) CFR positive (%) CFR (%)37.0 Incidence (k)242.9 Notifications (k)192.9 CDR (%) TB deaths = Incidence  Case fatality rate

Prevalence surveys: National blue; sub-national red. Kolin Size/Surveys

ARTI  50 Civil servants South Korea Size/Research 1

Calculating sample sizes Size/Research 2

Direction/Routine

Direction/OR

Decline in TB, Alaska Incidence or death rate/10K/year source: Grzybowski Tubercle 1976 deaths 30%/yr t 1/2 = 2.3 yr cases 13%/yr t 1/2 = 5 yr Direction/Surveys

Direction/Research TB: elimination by 2050? Incidence/million/yr Projected incidence 100x bigger than elimination threshold in 2050 GP2: incidence falls 5-6%/yr Vaccines, drugs and risk factors?

Nairobi Reasons/Routine

Smoking and TB in Chennai 27k deaths and 16k controls, k TB deaths Gajalakshmi, V., Peto, R., et al. Smoking and mortality from tuberculosis and other diseases in India: retrospective study of adult male deaths and controls Lancet (2003) –515. Smoker Non-smokerOdds TB deaths Controls OR = 5.9 (4.5) F = % of all TB deaths among men in Chennai are attributable to smoking Reasons/OR

Reasons/Surveys Drug Resistance in Retreatment Patients (n = 1 508) SA rates weighted by Province

TB incidence among gold miners in SA DDR Reasons/Research 1

Smear positive disease in South African gold miners Incidence (%/yr) Prevalence (%) Dis.Duration (yr) HIV HIV Ratio Corbett et al Reasons/Research 2

Dynamics of pulmonary TB in Peru Pulmonary TB cases/100,000 DOTS 1990 PTB falling at 6%/yr case finding Impact/Routine

Impact/OR

South Korea Impact/Surveys

Decline in prevalence Kolin, Czechoslovakia Men: 20%  10%/yr Women: 26%  21% China Impact/Research

The last word… We must eradicate tuberculosis, and we must do it now, … All available resources must be used. Chemotherapy, computers, prophylaxis and prevention, case finding and kindness can be blended in a properly constructed epidemiological model which will tell us exactly where we are going and how fast. Davies, J.C.A. The Eradication of Tuberculosis in Rhodesia DPH, London School of Hygiene and Tropical Medicine, 1966

Estimating CDR 1.Assume that the 1997 estimate of CDR is correct so that we know the incidence in Assume that the trend in total notifications (all forms; DOTS non-DOTS) gives the trend in incidence. 3.Use this trend to work out the incidence of all forms in the year Assume that the SS+ incidence is 45% of the all-forms incidence for HIV- people; 35% for HIV+ people. 5.Calculate the SS+ incidence 6.Divide the notification rate in DOTS areas by the SS+ incidence to get the SS+ DOTS case detection rate.

The Design Effect Suppose we have k clusters with m people in each cluster so that the total sample size is n = km. D = 1 + (m  1)ρ where ρ, the intra-class (or intra-cluster) correlation coefficient, is the ratio of the between-cluster variance s b to the total variance so that where s w is the within-cluster variance. 1.All members of a cluster are identical, sw = 0, r = 1 and D = m. Effective sample size = n/m = k = the number of clusters. 2.Members of each cluster have no particular similarity sb = 0, r = 0, and D = 1. Effective sample size = n = number of people. For example, if each cluster contains m = 10 people and ρ =0.1 then 1 + (m-1)ρ = 1.9. m = 20 people and ρ = 0.2 then 1 + (m – 1)ρ = 4.8 Even a small value of the intra-cluster correlation coefficient, multiplied by the size of the cluster, could lead to a substantial increase in variance and reduction in effective sample size.